Department of Biological Sciences and Engineering, Indian Institute of Technology, Palaj, Gandhinagar 382355, India.
Biochemistry. 2024 Oct 15;63(20):2542-2556. doi: 10.1021/acs.biochem.4c00427. Epub 2024 Sep 23.
Utilizing induced pluripotent stem cells (iPSCs) in drug screening and cell replacement therapy has emerged as a method with revolutionary applications. With the advent of patient-specific iPSCs and the subsequent development of cells that exhibit disease phenotypes, the focus of medication research will now shift toward the pathology of human diseases. Regular iPSCs can also be utilized to generate cells that assess the negative impacts of medications. These cells provide a much more precise and cost-efficient approach compared to many animal models. In this review, we explore the utilization of small-molecule drugs to enhance the growth of iPSCs and gain insights into the process of reprogramming. We mainly focus on the functions of small molecules in modulating different signaling pathways, thereby modulating cell fate. Understanding the way small molecule drugs interact with iPSC technology has the potential to significantly enhance the understanding of physiological pathways in stem cells and practical applications of iPSC-based therapy and screening systems, revolutionizing the treatment of diseases.
利用诱导多能干细胞(iPSCs)进行药物筛选和细胞替代疗法已经成为一种具有革命性应用的方法。随着患者特异性 iPSCs 的出现以及随后表现出疾病表型的细胞的发展,药物研究的重点现在将转向人类疾病的病理学。常规的 iPSCs 也可以用于生成评估药物负面影响的细胞。与许多动物模型相比,这些细胞提供了一种更精确和更具成本效益的方法。在这篇综述中,我们探讨了利用小分子药物来增强 iPSCs 的生长并深入了解重编程过程。我们主要关注小分子在调节不同信号通路方面的功能,从而调节细胞命运。了解小分子药物与 iPSC 技术的相互作用方式有可能极大地增强对干细胞中生理途径的理解以及基于 iPSC 的治疗和筛选系统的实际应用,从而彻底改变疾病的治疗方法。